Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LX211 for Active Sight-Threatening Non-Infectious Uveitis
2006-006543-31Phase 2Completed
- Sponsor
- Lux Biosciences, Inc.
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in uveitis comparing LX211 dose-ranging with Placebo (2 arms). Primary endpoint: Mean change from baseline in graded vitreous haze. Started Jan 2007; status: completed.
02
Drugs
voclosporin
03
Conditions
uveitis
Beyond the preview
Go deeper on 2006-006543-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006543-31.